Adial Pharmaceuticals, Inc · NASDAQ:ADIL
Adial Pharmaceuticals — Investor Presentation (January 2026)
18 slides from Adial Pharmaceuticals's investor presentation, January 2026
Slide 1: Medicines for Addiction
Medicines for Addiction Investor Presentation December 2021 January 2026 CONFIDENTIAL
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “might,” estimates,” “approximatel
Slide 3: Vision
Vision Adial is a Phase 3, clinical-stage biopharmaceutical company focused on developing genetically targeted therapies for alcohol use disorder and driving innovation in the prevention and treatment of addiction and related unmet medical needs. ADIAL PHARMACEUTICALS INC. | MEDICINES FOR ADDICTION
Slide 4: Alcohol Use Disorder is a Major Public Health Problem in the U.S.
Alcohol Use Disorder is a Major Public Health Problem in the U.S. Failure to help people with AUD is a major health, social and financial problem Excessive Alcohol Use: • Costs U.S. economy approximately $250 billion annually • 50% increase in prevalence from 2002 to 2013 • Contributes to over 200 d
Slide 5: Significant Segment of Market Not Being Addressed in U.S.
Significant Segment of Market Not Being Addressed in U.S. ~2.6M patients seeking treatment AUD • The vast majority of patients that have AUD remain undiagnosed and untreated, creating a large market opportunity for a product that can address patient needs • Excessive Alcohol Use accounts for ~5.3% o
Slide 6: Current Market Solutions are Failing
Current Market Solutions are Failing Current therapeutic approaches are significant barriers to patient adoption Abstinence Barrier Efficacy Barrier Abstinence is often the only goal, and current therapies Data show that current therapeutic solutions are ineffective require abstinence prior to initi
Slide 7: AD04 is Designed to Meet the Market Need
AD04 is Designed to Meet the Market Need Management of Heavy Drinking Reduction of Heavy Drinking Target Indication A new approach for patients who desire to Ends need for abstinence, a major hurdle in control drinking but cannot or will not starting & continuing pharmacologic therapy undertake exis
Slide 8: Genetic Test Expected to Drive Market Uptake
Genetic Test Expected to Drive Market Uptake Precision Medicine Enables: • Physician conversation with patient • First step of a test vs. a drug • Patient buy-in to treatment after positive test • Potential of increased compliance resulting in effective therapeutic The genetic test is expected to in
Slide 9: AD04 Expected Unique Profile Compared to Currently Approved Products
AD04 Expected Unique Profile Compared to Currently Approved Products Key anticipated unique selling points drive AD04 differentiation – expected to meet patient needs EU only ADO4* Selincro** Vivitrol Campral Revia Antabuse Novel Mechanism of Action Oral Dosing Designed to reduce Heavy Drinking No A
Slide 10: Target Market – Total Addressable Market (TAM) Potential
Target Market – Total Addressable Market (TAM) Potential U.S. Market $1.5B Patients seeking treatment for AUD Assuming only 14% (AG+) of Color Key: patients are treatable with AD04 Target Market Patients with AUD AD04, based on the genetic & with AD04 Target test, the total potential Genetics annual
Slide 11: ONWARD Phase 3 Study Conducted in Europe
ONWARD Phase 3 Study Conducted in Europe Trial Design • Randomized, double-blind, placebo-controlled, parallel- group multicenter study 37% 63% • Patients were screened for the appropriate genotypes via an inexpensive, standard blood test to determine eligibility for treatment with AD04 • Panel of 4
Slide 12: Specific Patient Sub-Groups Responded Well Based on U.S. Endpoint
Specific Patient Sub-Groups Responded Well Based on U.S. Endpoint Post Hoc Data Analysis Based on U.S. Endpoint Responder Analysis(1) (AG+ <10DDD) • U.S. Primary End Point: Responder Analysis, defined as the percentage of patients with 0 HDDs in the treatment arm versus placebo at a specific time po
Slide 13: Specific Patient Sub-Groups Responded Well Based on U.S. Endpoint
Specific Patient Sub-Groups Responded Well Based on U.S. Endpoint Post Hoc Data Analysis Based on U.S. Endpoint • U.S. Primary End Point: Responder Analysis, defined as the percentage of patients with 0 HDDs in the treatment arm versus placebo at a specific time point • AG+ subjects showed statistic
Slide 14: Significant Progress Made in 2025
Significant Progress Made in 2025 Laying the Groundwork to Advance AD04 to Phase 3 May 1: Adial Expands Intellectual June 16: Adial Submits February 19: Adial Awarded New Property Portfolio with New U.S. May 13: Adial Receives Briefing Package to U.S. Patent Covering Genotype- Patent Granted for Gen
Slide 15: Significant Progress Made in 2025 (cont.)
Significant Progress Made in 2025 (cont.) Laying the Groundwork to Advance AD04 to Phase 3 June 25: Adial Secures U.S.- August 6: Adial August 20: Adial Applauds U.S. October 9: Adial Based Manufacturing Through Announces Completion of Senate Support for Expanded Partners with Agreements with Cambre
Slide 16: Next Steps
Next Steps Finalize plans to begin Phase 3 Clinical Trial • Finalize Clinical Development Plan since receiving FDA feedback from EOP2 meeting • Protocol Approved FDA endorsed adaptive trial design, biomarker stratification, and target population • Endpoints Confirmed FDA validated primary endpoint o
Slide 17: Building an Addiction Focused Pharmaceutical Company
Building an Addiction Focused Pharmaceutical Company Lead Product for AUD • Large market with unmet need • Late-stage oral drug (Phase 3) • Companion diagnostic designed to identify responders • Seeking 505(B)(2) path to regulatory approval • Low-cost manufacturing • Licensed patent protection throu
Slide 18: Contact
Contact: adialpharma.com GENERAL INQUIRES: info@adialpharma.com INVESTOR RELATIONS: MEDIA RELATIONS: CrescendoCommunications,LLC Russo Partners,LLC 405 Lexington Ave 215 Park Ave South 9th Floor, Suite 9034 Suite 1905 New York, NY 10174 New York, NY 10003 T: 212-671-1021 T: 817-371-0654 ADIL@crescen
Adial Pharmaceuticals — Investor Presentation (January 2026) on 6ix